FBT news

First Trust NYSE Arca Biotechnology Index Fund · Biotechnology · United States

Stories about this fund's companies, ranked by fund weight and recency. Times are local.

Scienmag: Latest Science and Health News · 28 Oct 2026, 18:47 UTC
Nanopore Sequencing Delivers Full Pediatric Brain Tumor Workup in a Single
3.9% of FBT
Seeking Alpha · 28 Oct 2026, 20:02 UTC
Biogen anticipates $250M of run rate synergies by end of 2027 as it raises 2026 non-GAAP EPS to $12.20-$13 (NASDAQ:BIIB) | Seeking Alpha
3.4% of FBT
Seeking Alpha · 28 Oct 2026, 20:00 UTC
Biogen Inc. (BIIB) Q3 2026 Earnings Call Transcript | Seeking Alpha
3.4% of FBT
Seeking Alpha · 28 Oct 2026, 19:01 UTC
Biogen Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:BIIB) 2026-10-28 | Seeking Alpha
3.4% of FBT
Where to buy FBT
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
Investing.com · 28 Oct 2026, 13:52 UTC
Earnings call transcript: Biogen beats Q3 2026 estimates as growth portfolio expands By Investing.com
3.4% of FBT
Investing.com · 28 Oct 2026, 15:42 UTC
Incyte earnings up next: Analysts eye loss amid pipeline gains By Investing.com
3.2% of FBT
Where to buy FBT
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
wallstreet:online · 27 Oct 2026, 20:10 UTC
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
5.6% of FBT
Investing.com · 28 Oct 2026, 13:42 UTC
Exelixis stock hits all-time high at 65.62 USD By Investing.com
3.3% of FBT
Seeking Alpha · 28 Oct 2026, 21:30 UTC
Genmab A/S (GMAB) Discusses Phase III Cancer Data and Potential New Treatment Standards Transcript | Seeking Alpha
2.6% of FBT
Market Screener · 28 Oct 2026, 14:41 UTC
Adagene Inc. Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte?S Inca33890 in Patients with Microsatellite Stable Colorectal Cancer
3.2% of FBT
The Wall Street Journal · 28 Oct 2026, 11:09 UTC
Biogen Swings to Loss, Logs Higher Sales
3.4% of FBT
Aol · 28 Oct 2026, 19:44 UTC
Genmab Stock Hits 52-Week High - Here's Why
2.6% of FBT
Seeking Alpha · 28 Oct 2026, 11:04 UTC
Biogen posts Q3 beat on multiple sclerosis drugs (BIIB:NASDAQ) | Seeking Alpha
3.4% of FBT
RTTNews · 28 Oct 2026, 19:16 UTC
Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%
2.6% of FBT
Bloomberg Business · 28 Oct 2026, 10:15 UTC
Biogen Sales Top Estimates With Help From Newly Acquired Drugs
3.4% of FBT
Investing.com · 28 Oct 2026, 10:14 UTC
Biogen beats Q3 estimates, raises guidance floor on growth By Investing.com
3.4% of FBT
Investor's Business Daily · 28 Oct 2026, 10:10 UTC
Biogen Makes A Solid Return 'To Growth' -- What To Know
3.4% of FBT
Reuters · 28 Oct 2026, 10:09 UTC
Biogen beats third-quarter results on strength in rare disease drugs
3.4% of FBT
The Manila times · 28 Oct 2026, 11:11 UTC
Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte's INCA33890 in Patients with Microsatellite Stable Colorectal Cancer
3.2% of FBT
Benzinga · 28 Oct 2026, 17:44 UTC
Genmab Stock Hits 52-Week High - Here's Why - Genmab (NASDAQ:GMAB)
2.6% of FBT

FBT news

Where to buy FBT

Where to buy FBT